Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Common Equity (2020 - 2025)

Tarsus Pharmaceuticals has reported Common Equity over the past 6 years, most recently at $343.4 million for Q4 2025.

  • Quarterly results put Common Equity at $343.4 million for Q4 2025, up 52.95% from a year ago — trailing twelve months through Dec 2025 was $343.4 million (up 52.95% YoY), and the annual figure for FY2025 was $343.4 million, up 52.95%.
  • Common Equity for Q4 2025 was $343.4 million at Tarsus Pharmaceuticals, up from $335.1 million in the prior quarter.
  • Over the last five years, Common Equity for TARS hit a ceiling of $343.4 million in Q4 2025 and a floor of $147.7 million in Q2 2023.
  • Median Common Equity over the past 5 years was $208.1 million (2022), compared with a mean of $228.1 million.
  • Biggest five-year swings in Common Equity: soared 2402.49% in 2021 and later tumbled 33.31% in 2023.
  • Tarsus Pharmaceuticals' Common Equity stood at $166.7 million in 2021, then increased by 15.7% to $192.9 million in 2022, then rose by 2.12% to $197.0 million in 2023, then rose by 13.98% to $224.5 million in 2024, then soared by 52.95% to $343.4 million in 2025.
  • The last three reported values for Common Equity were $343.4 million (Q4 2025), $335.1 million (Q3 2025), and $332.6 million (Q2 2025) per Business Quant data.